BMO Capital Reiterates Regeneron Pharma (REGN) at Outperform, "Eylea Phase 2 Data Supportive of Likely Positive Phase 3"
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $780.00 price target on Regeneron Pharma (NASDAQ: REGN), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
